Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research
Shona A. Hendry, Roberto Salgado, Thomas Gevaert et al. · Advances in Anatomic Pathology · 2017
Assessment of tumor-infiltrating lymphocytes (TILs) in histopathologic specimens can provide important prognostic information in diverse solid tumor types, and may also be of value in predicting response to treatments. However, implementation as a routine clinical biomarker has not yet been achieved. As successful use of immune checkpoint inhibitors and other forms of immunotherapy become a clinical reality, the need for widely applicable, accessible, and reliable immunooncology biomarkers is clear. In part 1 of this review we briefly discuss the host immune response to tumors and different approaches to TIL assessment. We propose a standardized methodology to assess TILs in solid tumors on hematoxylin and eosin sections, in both primary and metastatic settings, based on the International Immuno-Oncology Biomarker Working Group guidelines for TIL assessment in invasive breast carcinoma. A review of the literature regarding the value of TIL assessment in different solid tumor types follows in part 2. The method we propose is reproducible, affordable, easily applied, and has demonstrated prognostic and predictive significance in invasive breast carcinoma. This standardized methodology may be used as a reference against which other methods are compared, and should be evaluated for clinical validity and utility. Standardization of TIL assessment will help to improve consistency and reproducibility in this field, enrich both the quality and quantity of comparable evidence, and help to thoroughly evaluate the utility of TILs assessment in this era of immunotherapy.
Cited by 709 works. doi:10.1097/pap.0000000000000162 Open-access PDF
Authors
- Shona A. Hendry
- Roberto Salgado
- Thomas Gevaert
- Prudence Anne Russell
- Bibhusal Thapa
- Michael Christie
- Koen K Van de Vijver
- Monica Valeria Estrada
- Paula I. González Ericsson
- Melinda E. Sanders
- Benjamin Solomon
- Cinzia Solinas
- Gert G. G. M. Van den Eynden
- Yves Allory
- Matthias Preusser
- Johannes Andreas Hainfellner
- Giancarlo Pruneri
- Andrea Vingiani
- Sandra Demaria
References
- PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
- The blockade of immune checkpoints in cancer immunotherapy
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients